Merus B.V. Aktie
WKN DE: A2AKFX / ISIN: NL0011606264
|
29.09.2025 03:49:15
|
Genmab In Advanced Talks To Acquire Merus : Report
(RTTNews) - Denmark's Genmab A/S (GMAB) is in advanced negotiations to acquire Merus NV (MRUS), a Dutch biopharmaceutical company developing treatments for head and neck cancer, Bloomberg reported citing people familiar with the matter.
Merus, listed on Nasdaq with a market capitalization of approximately $5.1 billion, has attracted takeover interest from several major pharmaceutical firms in recent weeks and may announce a deal within days, the report said.
If completed, the acquisition would mark the largest in Genmab's history.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merus B.V.mehr Nachrichten
Analysen zu Genmab A-S (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
| Genmab A-S (spons. ADRs) | 24,60 | 0,00% |
|
| Merus B.V. | 82,00 | 0,00% |
|